2025-11754NoticeWallet

FDA Offers Companies a Remote Checkup Instead of an Inspection

Published Date: 6/26/2025

Notice

Summary

The FDA just released clear guidance on how they’ll do remote regulatory assessments (RRAs) to check on products without visiting in person. This helps companies that make FDA-regulated products by making inspections easier and faster, especially during public health needs. The new rules start now, and businesses should get ready to work with remote checks, which could save time and money.

Analyzed Economic Effects

6 provisions identified: 4 benefits, 1 costs, 1 mixed.

Mandatory records requests expand to devices and BIMO

The guidance aligns with 2022 changes in law (the Food and Drug Omnibus Reform Act of 2022) that added device establishments and sites subject to bioresearch monitoring (BIMO) inspections to FDA's mandatory records-request authority under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act. The final guidance addresses the Agency's use of section 704(a)(4), including processes for firms to respond.

Electronic records and live data access rules clarified

The guidance clarifies mechanisms for electronic records reviews and the conditions under which FDA might access live data during a remote regulatory assessment, and it addresses concerns about confidentiality and security of establishment information reviewed by FDA. These points explain how and when electronic access to records may be used in RRAs.

FDA issues final RRA guidance

On June 26, 2025, the FDA published a final guidance titled "Conducting Remote Regulatory Assessments—Questions and Answers" that describes the Agency's current thinking on using remote regulatory assessments (RRAs) for FDA-regulated products. The guidance replaces a revised draft from January 26, 2024, and is intended to increase industry understanding of voluntary and mandatory RRAs.

Voluntary vs mandatory RRA participation clarified

The final guidance explicitly distinguishes between mandatory and voluntary RRAs and clarifies how FDA intends to inform establishments of the terms of participation in voluntary RRAs and obtain their consent. This explains the process firms can expect when FDA offers a voluntary remote assessment.

No Paperwork Reduction Act clearance required

The final guidance states it contains no collection of information and therefore does not require clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995. This means the guidance itself does not impose a new OMB information-collection burden.

FDA characterizes guidance as deregulatory

The FDA states that, after considering Executive Order 14192 and OMB guidance M-25-20, it finds this action to be deregulatory in nature. The Agency frames the final guidance as reducing regulatory burden in some manner.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
6/26/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register